Financial report for the period 1 January 2024 to 30 September 2024 &nb...
Illumina, Inc. shared its financial results for the third quarter of fiscal year 2024, demonstrating resilience amidst macroeconomic challenges and...
Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24%compared to the third quarter of 2023 Placed seven Growth Direct&...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, reported its consolidated financial results for the third quarter...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced financial r...
Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7% Net income of $57.8 million; Adjusted EBITDA of $302.5 milli...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported its financial results for the third quarter ended September 28, ...
Roche’s latest financial report highlights its robust performance, driven by innovation in its pharmaceutical and diagnostics divisions, while navi...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive topline one-year results from the open-label, single-arm phase IV ELEVATUM study evaluating Vabysmo&r...
Telix Pharmaceuticals provides an update on its revenue and operational performance for the quarter ended 30 September 2024 (Q3 2024). Revenue update, f...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
Financial results of Q2 2024 Group net sales up organically by 1.7% to € 5.4 billion EBITDA pre down 0.8% organically to € 1...
– Record revenue of $81.5M in 3QFY24, an increase of 28% over $63.7M in 3QFY23 – – Gross margin improved to 43.3% in 3QFY24, incre...
© 2025 Biopharma Boardroom. All Rights Reserved.
